chlorthenoxazin: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 8602 |
| CHEMBL ID | 124815 |
| CHEBI ID | 134882 |
| SCHEMBL ID | 25595 |
| MeSH ID | M0049957 |
| Synonym |
|---|
| reugaril |
| 4-oxo-2-(beta-chloroethyl)-2,3-dihydrobenzo-1,3-oxazine |
| chlorthenoxazine [inn] |
| chlorthenoxazinum [inn-latin] |
| brn 0170863 |
| einecs 205-082-3 |
| 4h-1,3-benzoxazin-4-one, 2-(2-chloroethyl)-2,3-dihydro- |
| 2-(2-chloroethyl)-2,3-dihydro-4-oxo-1,3-benzoxazine |
| 2-(beta-chloroethyl)-2,3-dihydro-4-oxo(benzo-1,3-oxazine) |
| nsc 525254 |
| 2-(2-chloroethyl)-2,3-dihydro-4h-1,3-benzoxazin-4-one |
| clortenoxazina [inn-spanish] |
| betix |
| ossipirina |
| ossazone |
| reulin |
| wln: t66 bvm eo dhj d2g |
| reumagrip |
| nsc-525254 |
| 2-(2-chloroethyl)-3-aza-4-chromanone |
| 2-(2-chloroethyl)-2,3-benzoxazin-4-one |
| 2-(2-chloroethyl)-2,3-benzoxazine |
| valtorin |
| apirazin |
| 4h-1, 2-(2-chloroethyl)-2,3-dihydro- |
| chlorthenoxazine |
| valmorin |
| 2-(.beta.-chloroethyl)-2,3-oxazine) |
| 132-89-8 |
| nsc525254 |
| 4-oxo-2-(.beta.-chloroethyl)-2,3-oxazine |
| chlorethylbenzmethoxazone |
| ap 67 |
| chlorthenoxazin |
| CHEBI:134882 |
| 2-(2-chloroethyl)-2,3-dihydro-1,3-benzoxazin-4-one |
| CHEMBL124815 , |
| ap-67 |
| benzmethoxazone |
| piroxina |
| chlorthenoxazin(e) |
| bdbm50106191 |
| 2-(2-chloro-ethyl)-2,3-dihydro-benzo[e][1,3]oxazin-4-one (chlorthenoxazin) |
| 4h-1,3-benzoxazin-4-one, 2,3-dihydro-2-(2-chloroethyl)- |
| niosh/dm3743000 |
| DM37430000 |
| 2-(2-chloroethyl)-2h-1,3-benzoxazin-4(3h)-one |
| chlorthenoxazinum |
| chlorthenoxazine [inn:ban] |
| ka0b657lv3 , |
| clortenoxazina |
| 4-27-00-02766 (beilstein handbook reference) |
| unii-ka0b657lv3 |
| chlorthenoxazine [who-dd] |
| chlorthenoxazine [mart.] |
| chlorthenoxazin(e) [mi] |
| SCHEMBL25595 |
| 2-(beta-chlorathyl)-2,3-dihydro-4-oxobenz-1,3-oxazin |
| 2-(.beta.-chloroethyl)-2,3-dihydro-4-oxo(benzo-1,3-oxazine) |
| component of fiobrol (salt/mix) |
| ossapirina |
| component of trigatan (salt/mix) |
| YEKMWXFHPZBZLR-UHFFFAOYSA-N |
| 4-oxo-2-(.beta.-chloroethyl)-2,3-dihydrobenzo-1,3-oxazine |
| 2-(2-chloroethyl)-2h-benzo[e][1,3]oxazin-4(3h)-one |
| HY-101751 |
| CS-6577 |
| Z1269198910 |
| DTXSID70861786 |
| AKOS034122341 |
| Q27282145 |
| EX-A4522 |
| 2-(2-chloroethyl)-3,4-dihydro-2h-1,3-benzoxazin-4-one |
| EN300-257452 |
| Class | Description |
|---|---|
| benzoxazine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | IC50 (µMol) | 8.5000 | 0.0002 | 0.8123 | 9.8100 | AID154621 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID493017 | Wombat Data for BeliefDocking | 2001 | Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23 | Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis. |
| AID154621 | The compound was tested for poly(ADP-ribose)-polymerase (PARP) inhibition | 2001 | Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23 | Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.25) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||